Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

The first amylin drug was introduced to the market some 20 years ago ... The Danish drugmaker has already struggled to meet ...